Anti-Infective Drugs Market Report 2025 (Global Edition)

Anti-Infective Drugs Market Report Description

We have various report editions of Anti-Infective Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Competitive Landscape: The Anti-Infective Drugs market

The Anti-infective drugs market has intense competition in the market. Along with focusing on introducing new, technologically sophisticated products, the major competitors in the market are working hard to increase their footprint in emerging areas through new alliances and merger acquisitions. The key players implement various strategies such as acquisitions, mergers, and partnerships with other key market players.
For instance, in July 2023, AiCuris Anti-infective Cures AG reported that it had sharpened its strategic focus on the development of novel, therapeutic candidates for the prevention and treatment of moderate to severe and potentially life-threatening infectious diseases in immunocompromised patients.
Source:(https://www.aicuris.com/81n219/AiCuris-Announces-Strategic-Shift-to-Focus-Development-and-Commercialization-of-Anti-infectives-for-Immunocompromised-Patients)
 

Top Companies Market Share in Anti-Infective Drugs Industry: (In no particular order of Rank)

• Novartis AG
• Merck & Co.
• Inc
• Alcon Pharmaceuticals Ltd
• Quest Diagnostics Inc.
• AstraZeneca Plc
• Sanofi
• GlaxoSmithKline plc
• Gilead Sciences
• Novartis AG
• Cipla
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of Anti-Infective Drugs Market

Which Region Will Dominate the Market in 2024?

According to Cognitive Research, the North American region dominated the Anti-infective drugs market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. One of the main drivers of the North American anti-infective agent market's expansion is the rising incidence of chronic illnesses. Chronic illnesses are disorders that progress over time as a result of a confluence of behavioral, physiological, environmental, and genetic factors. Diabetes, cancer, cardiovascular disorders (including heart attacks and stroke), and chronic respiratory illnesses (including asthma and chronic obstructive pulmonary disease) are the four main categories of noncommunicable diseases (NCDs). Drugs classified as anti-infective that prevent or treat infections include those with antibacterial, antiviral, antifungal, and anti-parasitic properties. Chemically produced antimicrobial drugs known as antibiotics eliminate or stop the development of bacteria, curing and preventing bacterial infections. Macrolides, which include erythromycin, clarithromycin, and azithromycin, are the primary groups of antibiotics that have traditionally been investigated for their possible use in the secondary prevention of coronary heart disease. The anti-proliferative, pro-apoptotic, and anti-epithelial-mesenchymal-transition (EMT) characteristics of some antibiotics have been used in cancer therapy. Thus, the market for anti-infective drugs in North America is being driven by the rising frequency of chronic illnesses.
For instance, in July 2022, Pfizer Inc. and BioNTech SE announced the U.S. Food and Drug Administration (FDA) approved the companies’ supplemental Biologics License Application (sBLA) for their COVID-19 vaccine, known as COMIRNATY (COVID-19 Vaccine, mRNA), to include individuals 12 through 15 years of age. The vaccine was previously made available to this age group in the U.S. under emergency use authorization (EUA), and to date, more than 9 million 12- to 15-year-old adolescents in the U.S. have completed a primary series.
Source:(https://www.pfizer.com/news/announcements/pfizer-and-biontech-announce-us-fda-approval-their-covid-19-vaccine-comirnatyr#:~:text=Pfizer%2DBioNTech%20COVID%2D19%20Vaccine,months%20of%20age%20and%20older.)
For instance, in May 2022, The US Food and Drug Administration (FDA) removed the clinical hold on Gilead Sciences’ Investigational New Drug Application (IND) of injectable lenacapavir for treating and preventing human immunodeficiency virus (HIV) infection.
Source:(https://www.clinicaltrialsarena.com/news/fda-hold-gilead-lenacapavir/)

Which Region Is Expanding at The Fastest CAGR?

The Asia Pacific region's anti-infective drugs market is expected to experience the fastest growth rate with a CAGR of XX% during the forecast period. The Asia Pacific anti-infective agents market is expanding due in large part to ongoing research and development of novel anti-infective agents. Recent advancements in the medical device sector have encouraged both long-standing competitors and recent newcomers to launch their innovative goods. There have also been several advancements in the methods used in medical exams. The development and introduction of anti-infective medications by market participants is being encouraged by the use of longer-lasting illuminating light sources in gynecological operations. With innovative features and technology, vendors may grow their clientele and have a stronger presence in developing markets. The Asia Pacific anti-infective agents market is probably going to be driven by this aspect.
For instance, in July 2023, Lupin Limited reported that it had received tentative approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA), Dolutegravir Tablets for Oral Suspension, 5 mg to treat HIV/AIDS. 
Source:(https://www.lupin.com/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-tablets-for-oral-suspension/)
For instance, in March 2023, Shionogi Announces Xocova (Ensitrelvir Fumaric Acid) Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection
Source:(https://www.shionogi.com/global/en/news/2024/03/20240305.html)
 

The current report Scope analyzes Anti-Infective Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Anti-Infective Drugs Market Analysis

Segment Performance in The Anti-Infective Drugs Market

Product Type Segment Analysis

The antiviral segment dominates the anti-infective market due to the high prevalence of viral infections such as HIV, hepatitis, and influenza. Additionally, the development of antiviral drugs targeting specific viral enzymes or replication processes has led to effective treatments for various viral infections, driving demand and market dominance.
For instance, in January 2022, UNICEF signed several LTA (long-term agreements) with suppliers for the procurement of Molnupiravir, a new antiviral medicine.
Source:(https://www.unicef.org/topics/covid-19?f%5B0%5D=type_of_content%3A820909bc-920f-423b-8dfa-cd3ea253ea5e)

For instance, in October 2021, Merck & Co., Inc. signed a voluntary licensing agreement with Medicines Patent Pool (MPP), a United Nations-backed public health organization. The agreement facilitates affordable global access to Molnupiravir, which is an investigational oral COVID-19 antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults. These initiatives are likely to boost the antiviral drugs segment growth during the forecast period.
Source:(https://www.merck.com/news/the-medicines-patent-pool-mpp-and-merck-enter-into-license-agreement-for-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-to-increase-broad-access-in-low-and-middle-income-countri/)

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Anti-Infective Drugs Industry. Request a Free Sample PDF!

Distribution Channel Segment Analysis

The hospital pharmacy segment dominates the anti-infective market because hospitals are primary settings for treating severe infections and managing outbreaks. Hospitals require a constant supply of anti-infective drugs to treat patients with various infectious diseases, including those with multidrug-resistant pathogens. Additionally, hospitals have stringent infection control protocols, necessitating a reliable and diverse inventory of anti-infective medications, thus driving market dominance in this segment. Due to the rise in hospital admissions around the globe. Hospital pharmacies are preferred by patients because they offer comprehensive patient treatment, and care, prompt reimbursement, and insurance policies. Hospital pharmacies are usually connected to bigger healthcare facilities that include state-of-the-art amenities. Patients with serious illnesses are treated in specialist departments, such as critical care units or infectious disease departments, which are frequently found in these institutions.
 

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Anti-Infective Drugs Indication Segment Analysis

Indication Segment Analysis

The sepsis segment dominates the anti-infective market because sepsis is a life-threatening condition caused by the body's response to an infection, often leading to organ dysfunction and death if not treated promptly. The complexity and severity of sepsis require aggressive antimicrobial therapy, including broad-spectrum antibiotics, making it a significant driver of demand in the anti-infective market.
For instance, in May 2024 according to the World Health Organization, Almost half (20 million) of all estimated sepsis cases worldwide occurred in children under 5 years of age. For every 1000 hospitalized patients, an estimated 15 patients will develop sepsis as a complication of receiving health care. From data published in 2020, there were 48.9 million cases and 11 million sepsis-related deaths worldwide, representing 20% of all global deaths
Source:(https://www.who.int/news-room/fact-sheets/detail/sepsis)

• HIV Infection
• Pneumonia
• Respiratory Virus Infection
• Sepsis
• Tuberculosis
• Other Indications

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion